GRF News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GR

Mkt Cap

$39.5M

Volume

11.60K

Loading chart

GR

GRFEagle Capital Growth Fund, Inc.

GRF

Pay with—

Available Balance0.00

GR

AUM

$39.1M

Volume

11.60K

Yield

8.47%

Chart Earnings News About Dividends Insider Filings

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven yearsBARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo® during the next seven years, following recent Food and Drug Administration (FDA) approval to treat primary immunodeficiencies (PID).GlobeNewswire Inc. · Jul 1, 2024

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier GroupBARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corporation (Haier Group) and forged a strategic alliance with Haier Group. The deal has received all necessary regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange.GlobeNewswire Inc. · Jun 18, 2024

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficienciesBARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID).GlobeNewswire Inc. · Jun 17, 2024

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celebrated the 50th anniversary of its flagship site in Clayton, N.C., whose production of these essential therapeutics during its existence has saved the lives of millions of patients.GlobeNewswire Inc. · Apr 18, 2024

Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CEBARCELLONA, Spagna, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), uno dei principali produttori mondiali di farmaci plasmaderivati e di soluzioni diagnostiche innovative, ha annunciato in data odierna che il suo nuovo Procleix ArboPlex Assay ha ottenuto il marchio CE ai sensi della normativa sulla diagnostica in vitro (IVDR), il primo per un test automatico NAT convalidato specificamente per lo screening dei donatori di sangue al fine di rilevare quattro arbovirus principali: Chikungunya, Dengue, West Nile e Zika.GlobeNewswire Inc. · Apr 4, 2024

Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CEBARCELONE, Espagne, 04 avr. 2024 (GLOBE NEWSWIRE) -- Grifols (MCE : GRF, MCE : GRF. P NASDAQ : GRFS), l’un des principaux producteurs mondiaux de médicaments dérivés du plasma et de solutions de diagnostic innovantes, a annoncé, ce jour, que son nouveau test Procleix ArboPlex Assay avait obtenu le marquage CE dans le cadre du règlement relatif aux dispositifs médicaux de diagnostic in vitro (IVDR), le premier pour un test d’acide nucléique (NAT) automatisé spécifiquement validé pour le dépistage des donneurs de sang afin de détecter quatre arbovirus majeurs : les virus du chikungunya, de la dengue, du Nil occidental et du Zika.GlobeNewswire Inc. · Apr 4, 2024

Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von ArbovirenBARCELONA, Spanien, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), eines der weltweit führenden Unternehmen in der Herstellung von Plasmamedikamenten und innovativen Diagnostik-Lösungen, gab heute bekannt, dass sein neuer Procleix ArboPlex Assay die CE-Zertifizierung gemäß der Verordnung über In-vitro-Diagnostika (IVDR) erhalten hat.GlobeNewswire Inc. · Apr 4, 2024

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningBARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR), the first for an automated nucleic acid test (NAT) specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.GlobeNewswire Inc. · Apr 4, 2024

Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírusBARCELONA, Espanha, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), um dos principais produtores mundiais de medicamentos derivados do plasma e de soluções de diagnóstico inovadoras, anunciou hoje que o seu novo Procleix ArboPlex Assay obteve a marca CE ao abrigo do Regulamento de Diagnóstico In Vitro (IVDR), o primeiro para um teste automatizado de ácido nucleico (NAT) especificamente validado para o rastreio de dadores de sangue para detetar quatro arbovírus principais: chikungunya, dengue, vírus do Nilo Ocidental e vírus Zika.GlobeNewswire Inc. · Apr 4, 2024

Grifols shares rebound after KPMG greenlights accounts The Barcelona company has seen share price collapse since publication of a report from Gotham City Research in JanuaryMarketWatch · Mar 8, 2024

to start trading

GR

GRFEagle Capital Growth Fund, Inc.

GRF

Pay with—

Available Balance0.00

Your PositionYou don't own any GRF yet.

Related Tickers

Earnings

Dividends

Last · Nov 21

Amount$0.85

Yield8.47%

Annual$0.85